Tesla analyst cuts Model 3 forecast, now sees bear market in stock ahead

  • 📰 CNBC
  • ⏱ Reading Time:
  • 41 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 20%
  • Publisher: 72%

Finance Finance Headlines News

Finance Finance Latest News,Finance Finance Headlines

RBC Capital Markets says delivery issues and lackluster demand will plague Tesla earnings; analyst Spak cuts his stock forecast 14 percent.

Lackluster demand and overseas Model 3 delivery problems will weigh on Tesla's first-quarter earnings results when the company reports in April, RBC Capital Markets warned clients Monday.

"We see both 2019 and 2020 revenue as down vs. the 4Q18 run-rate and, given Tesla is priced for growth, believe the valuation will come in," analyst Joseph Spak wrote in a note to clients."Overall, for 2019 we now forecast about 261,000 Model 3 [deliveries], down from 268,000 prior. Our 2020 forecast of 347,500 remains unchanged."

"Regionally, we assume 21,000 units in Europe, 6,000 to 7,000 in China and the remainder in North America," Spak wrote."In China, some deliveries were delayed because of a customs issue." "Our 2019 Model 3 average selling price is now $53,600, down from $55,500 prior – still stronger in the first half as Tesla fulfills higher-end demand internationally before lower priced models kick in," Spak said.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Analyst cut Model 3 forecast once before and has no evidence to support this new decision to cut. Evidence suggests Model 3 sales in Feb were huge in Europe and China. Analysts missed Tesla deliveries forecast by wide margin in 2018 and are still working with flawed fcast model.

Model 3 has an ugly nose.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 12. in FİNANCE

Finance Finance Latest News, Finance Finance Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Biogen stock plunge shows 'investment model in drug development is all wrong,' says former Aetna CEOFormer Aetna Chairman and CEO Mark Bertolini says investors currently are trading 'on a basis that says, 'does this drug work today? Did this trial pass today?'''
Source: CNBC - 🏆 12. / 72 Read more »